REMARKABLE
17.3.2020 14:02:06 CET | Business Wire | Press release
reMarkable today announced its next-generation paper tablet, reMarkable 2. The breakthrough device for note-taking and reviewing documents without distractions comes from the Norwegian developers behind the original paper tablet, which broke pre-order records during its 2017 launch.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200317005154/en/
reMarkable 2 is available for pre-order from reMarkable.com for €399, and is set to ship in June 2020. The limited-time launch offer will include a Marker and Folio.
At 0.19 in/4.7 mm thick, reMarkable 2 is the world’s thinnest tablet. Armed with weeks of battery life, and the breakthrough second-generation CANVAS display partially powered by E Ink technology, reMarkable 2 is the most paper-like digital device the industry has ever seen.
“reMarkable 2 supports our design philosophy of helping people think better through powerful technology,” said Magnus Wanberg, CEO of reMarkable. “Our latest tablet is paper-thin and our innovations in display technology make it so much like writing on paper that it’s hard to tell the difference.”
Inspired by paper, reMarkable 2 is a tool for note-taking, reading, and annotating documents without built-in distractions. “Today’s world is a frenzied place of ever-evolving technology that increasingly demands more of our time and attention. reMarkable 2 is a step in a more human-friendly direction. It’s designed to help people think,” said Wanberg.
The company has spent the last six years developing and perfecting its breakthrough paper tablet to deliver a realistic paper experience that supports improved focus and better thinking, while still maintaining a connection to the digital world.
reMarkable 2 features the ability to convert handwritten notes into text, along with options for organizing, sharing, annotating and searching documents. Among a host of other digital features, reMarkable’s cloud service makes content accessible through multi-platform companion apps for desktop and mobile. Its feature set is aimed at anyone who likes writing by hand, but wants to be able to reuse their work in their digital workflow.
At launch, reMarkable 2 will be accompanied by a Google Chrome plug-in that will allow users to read clean, reformatted web articles on their paper tablet without distractions.
Innovations in ultra-thin, high-friction surface materials and a completely redesigned, second-generation CANVAS display, make reMarkable 2 an unprecedented digital paper device. Millions of physical ink particles lift to the display’s surface, working in tandem with the high precision Marker to deliver exceptional paper-like accuracy.
A range of accessories to compliment reMarkable 2
All accessories are either included in their respective launch bundles, available as a bundle upgrade, or can be purchased separately later in the year when the pre-order finishes.
Markers:
reMarkable 2 will launch with two different Markers, both of which attach magnetically to the right side of the paper tablet:
Marker - €59 (included in pre-order)
Marker Plus (includes built-in eraser in the top end) - €99
Folios
: Folio and Book Folio have been created with function and style in mind. They’re both made from fine materials and designed to fit reMarkable 2 perfectly.
Folio - €79 - The original sleeve for reMarkable 2 (included in the first part of pre-order)
Book Folio - from €99 - Lets you keep your reMarkable 2 in its cover while working. Attaches magnetically to reMarkable 2
About reMarkable
Based in Oslo, Norway, reMarkable is the leading innovator within the paper tablet category, developing breakthrough digital paper tablets for note-taking, reading, and reviewing documents. Its vision is to create human-friendly products to help people think better. For more information about reMarkable and its digital paper tablet, visit https://remarkable.com
YouTube: https://youtu.be/0dgXuStEm4U
Instagram: https://www.instagram.com/remarkable/
Facebook: https://www.facebook.com/remarkableAS
Twitter: https://twitter.com/remarkablepaper
#remarkablepaper
View source version on businesswire.com: https://www.businesswire.com/news/home/20200317005154/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom